Cytek Biosciences (CTKB) Capital Expenditures Growth (3y) (2023 - 2026)
Cytek Biosciences (CTKB) Capital Expenditures Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.64% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 8.49% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 16.83% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 1.81% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 0.84% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 2.15% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 7.57% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytek Biosciences | 586.89 Mn | 521.19 Mn | 21.25 Mn | 149.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 149.85% |
| Dec 31, 2025 | -34.85% |
| Sep 30, 2025 | 39.96% |
| Jun 30, 2025 | -28.12% |
| Mar 31, 2025 | 0.87% |
| Dec 31, 2024 | -60.81% |
| Sep 30, 2024 | -36.75% |
| Jun 30, 2024 | 101.31% |
| Mar 31, 2024 | 3.66% |
| Dec 31, 2023 | -32.24% |
| Sep 30, 2023 | 87.37% |